Valuation: Mendus AB

Market Cap 38Cr 3.91Cr 3.42Cr 3.16Cr 2.95Cr 5.56Cr 369.69Cr 5.68Cr 15Cr 182.38Cr 15Cr 14Cr 633.21Cr P/E 2026 *
-4.06x
P/E 2027 * -6.9x
Enterprise Value 5.91Cr 60.72L 53.16L 49.08L 45.83L 86.27L 57Cr 88.24L 2.28Cr 28Cr 2.28Cr 2.23Cr 98Cr EV / Sales 2026 *
6.6x
EV / Sales 2027 * 0.82x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day-6.45%
1 week-17.61%
Current month+1.93%
1 month+1.93%
3 months+30.78%
6 months+5.45%
Current year+3.57%
1 week 5.55
Extreme 5.55
7.07
1 month 4.9
Extreme 4.9
7.49
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/22/28Buy

Chief Technology Officer

10,000 0.0050%
24/22/24Buy

Chief Financial Officer

10,000 0.0050%
24/22/24Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-6.45%-17.61%-27.04%-44.23% 3.92Cr
+0.94%+7.83%-4.50%+3.17% 4.62TCr
+2.78%+12.12%+405.33%+609.04% 3.87TCr
+0.05%+13.76%+21.14%-13.78% 3.19TCr
+2.73%+5.53%+18.49%+60.60% 3.11TCr
+8.02%+5.23%+17.67%+35.36% 2.38TCr
+0.34%+14.22% - - 1.62TCr
-0.06%+15.30%+67.39%+123.62% 1.51TCr
-1.13%+7.40%+12.81%+20.67% 1.37TCr
-0.46%+6.29%+104.15%+96.21% 1.34TCr
Average +0.61%+9.38%+68.38%+98.96% 2.3TCr
Weighted average by Cap. +1.66%+10.07%+92.26%+137.61%

Financials

2026 *2027 *
Net sales 89.5L 9L 8L 7L 7L 13.07L 8.7Cr 13.37L 34.55L 4.29Cr 34.55L 33.79L 15Cr 22Cr 2.31Cr 2.02Cr 1.87Cr 1.74Cr 3.28Cr 218.2Cr 3.35Cr 8.67Cr 107.65Cr 8.67Cr 8.48Cr 373.74Cr
Net income -16Cr -1.68Cr -1.47Cr -1.35Cr -1.26Cr -2.38Cr -158.39Cr -2.43Cr -6.29Cr -78Cr -6.29Cr -6.15Cr -271.3Cr -1.86Cr -19.11L -16.73L -15.45L -14.43L -27.15L -18Cr -27.77L -71.76L -8.91Cr -71.77L -70.19L -31Cr
Net Debt -32Cr -3.3Cr -2.89Cr -2.67Cr -2.49Cr -4.69Cr -312.29Cr -4.8Cr -12Cr -154.06Cr -12Cr -12Cr -534.89Cr -20Cr -2.03Cr -1.77Cr -1.64Cr -1.53Cr -2.88Cr -191.48Cr -2.94Cr -7.61Cr -94Cr -7.61Cr -7.44Cr -327.97Cr
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
29/26/29 SEK 5.800 -6.45% 41,496
26/26/26 SEK 6.200 -4.91% 29,388
25/26/25 SEK 6.520 -1.36% 24,399
24/26/24 SEK 6.610 +1.69% 22,489
23/26/23 SEK 6.500 -7.67% 64,342
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.200SEK
Average target price
16.00SEK
Spread / Average Target
+158.06%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock